Plain-English translation of NCT07259317 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether a new medication called , when given alongside two standard chemotherapy drugs ( and ), can help treat advanced pancreatic cancer. The study will first find the right dose of the medication that is safe and effective, then test it in a larger group of patients. The goal is to see if this combination works better than chemotherapy alone.
Pancreatic cancer is very difficult to treat, and current chemotherapy options don't work well enough for many patients. This trial exists to test whether adding this new medication might help the chemotherapy work better and improve outcomes for people with advanced pancreatic cancer.
You likely qualify if…
You likely don't qualify if…
You will receive the new medication by mouth once daily for 3 days (the day before, the day of, and the day after each chemotherapy session), along with the two standard chemotherapy drugs given intravenously. The study has two parts: first, a small group of patients will help doctors find the safest and best dose; then, a larger group will receive that optimized dose. You will have regular visits for treatment and monitoring to check how well the combination is working and watch for side effects.
AI-generated summary from trial data · Oct 2, 2026 · Not medical advice
United States